Fig. 1

Mechanism of acquired VEN-R in AML. a No BCL2^Mut was found in patients with acquired VEN-R AML. b Changes in the types of mutational genes in our AML cohort according to VEN-R. c The acquired TP53 mutation played a dominant role in the relapse of Pt #8. d Reconstructed existing mutations (EM), especially conversed dominant mutation (DM), were important in acquired VEN-R. e-g Expanded FLT3-ITD-mediated acquired VEN-R in Pt #3 (e), #6 (f), and #7 (g). h The proportion of reconstructed existing mutations in Pt #1